Finanzen von Insmed Inc (INSM)INSMInsmed Inc

Insmed Incorporated (INSM) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Arikayce, accounting for 80.3% of total sales, equivalent to $114.29M. Another important revenue stream is Brinsupri. Understanding this composition is critical for investors evaluating how INSM navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Insmed Incorporated maintains a gross margin of 83.71%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -23.81%, while the net margin is -3.11%. These profitability ratios, combined with a Return on Equity (ROE) of -87.22%, provide a clear picture of how effectively INSM converts its operational activities into shareholder value.

In the context of the broader market, INSM competes directly with industry leaders such as VTRS and HCM. With a market capitalization of $20.89B, it holds a significant position in the sector. When comparing efficiency, INSM's gross margin of 83.71% stands against VTRS's 42.03% and HCM's 45.32%. Such benchmarking helps identify whether Insmed Incorporated is trading at a premium or discount relative to its financial performance.

Insmed's gross margin is strong at 83.76% in Q2 2026, but it has reported substantial net losses, with a net income of -13,242,000 USD in the same quarter. The company has shown significant revenue growth, reaching 425,486,000 USD in Q2 2026, but still struggles with profitability.